DanCann Pharma Past Earnings Performance
Past criteria checks 0/6
DanCann Pharma's earnings have been declining at an average annual rate of -61.8%, while the Pharmaceuticals industry saw earnings growing at 13.1% annually. Revenues have been growing at an average rate of 39.2% per year.
Key information
-61.8%
Earnings growth rate
11.6%
EPS growth rate
| Pharmaceuticals Industry Growth | 7.3% |
| Revenue growth rate | 39.2% |
| Return on equity | -931.5% |
| Net Margin | -719.1% |
| Next Earnings Update | 29 Nov 2024 |
Recent past performance updates
Recent updates
Revenue & Expenses Breakdown
How DanCann Pharma makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Jun 24 | 8 | -59 | 8 | 0 |
| 31 Mar 24 | 7 | -61 | 8 | 0 |
| 31 Dec 23 | 7 | -62 | 9 | 0 |
| 30 Sep 23 | 7 | -15 | 9 | 0 |
| 30 Jun 23 | 8 | -15 | 9 | 0 |
| 31 Mar 23 | 7 | -16 | 9 | 0 |
| 31 Dec 22 | 7 | -16 | 9 | 0 |
| 30 Sep 22 | 7 | -15 | 8 | 0 |
| 30 Jun 22 | 4 | -15 | 8 | 0 |
| 31 Mar 22 | 4 | -13 | 8 | 0 |
| 31 Dec 21 | 2 | -12 | 7 | 0 |
| 30 Sep 21 | 1 | -9 | 5 | 0 |
| 31 Mar 21 | 0 | -6 | 4 | 0 |
| 31 Dec 20 | 0 | -4 | 3 | 0 |
| 30 Sep 20 | 0 | -2 | 2 | 0 |
| 31 Dec 19 | 0 | 0 | 0 | 0 |
Quality Earnings: DAN is currently unprofitable.
Growing Profit Margin: DAN is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: DAN is unprofitable, and losses have increased over the past 5 years at a rate of 61.8% per year.
Accelerating Growth: Unable to compare DAN's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: DAN is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (28.7%).
Return on Equity
High ROE: DAN has a negative Return on Equity (-931.47%), as it is currently unprofitable.